Unpacking the Pipeline: Clearway Health’s Expert Insights on Specialty Medications
Key Takeaways
- Specialty medications are driving innovation in patient care across multiple disease states. New FDA-approved therapies for oncology, rare diseases, COPD, hemophilia, cystic fibrosis, cardiovascular disease and other complex conditions are expanding treatment options and improving outcomes for patients with previously limited therapeutic choices.
- Hospitals and health systems must prepare for a rapidly evolving specialty pharmacy landscape. Understanding emerging medications, biosimilars, orphan drugs and first-in-class therapies is critical for healthcare organizations seeking to expand formulary access, support clinical excellence, and meet growing patient demand for advanced treatments.
- Specialty pharmacy programs help accelerate patient access to breakthrough therapies. By providing expertise in medication evaluation, formulary integration and patient access strategies, specialty pharmacy partners enable hospitals and health systems to deliver innovative treatments faster while improving patient outcomes and strengthening organizational performance.
Our 10 Most Anticipated Specialty Pharmacy Medications in 2025
Clearway Health's specialty pharmacy services create sustainable assets and build lasting legacies for hospitals and health systems, providing a service that every patient deserves. Our team began at Boston Medical Center Health System, improving access to care and managing the complex medication needs of vulnerable patient populations. Our exclusive focus is transforming specialty pharmacy, and we have proven expertise and results in expanding our partner clients’ access to vital new medications approved by the FDA. This has a waterfall effect of expanding patient access to the latest and most innovative medications, improving their health outcomes and the overall vitality of the organizations and communities we serve.
Our specialty pharmacy team are experts in new medications that are recently approved or available in the market, as well as what’s up and coming. In areas like oncology, biosimilars, rare disease orphan drugs and new medications for COPD, hemophilia, cystic fibrosis and heart disease, there’s been significant progress in medication therapies. We help our partner clients understand the landscape and navigate how to add these medications to their formularies so their patients can see the benefits faster.
2024 delivered notable advancements in the FDA approval of treatments for rare diseases, with 43% of all novel drug approvals classified as first-in-class and 54% designated as orphan drugs. These approvals offer new hope to patients with conditions that previously had limited therapeutic options. Here are 10 growth driver specialty medications we are closely tracking and educating our hospital and health system partners about. Together, we pioneer providing innovative therapies to deliver optimal clinical outcomes to every patient, every time.